---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020834"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:42:46.836216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end

## Summary
- CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.
- Exa-cel rolling FDA review starts Nov; complete submission due Q1 2023; EMA/MHRA submissions by year-end.
- CTX112 (next-gen CAR-T) IND cleared; Phase 1 expected H1 2023.
- VCTX211 (T1D stem-cell therapy) CTA cleared by Health Canada.
- CTX110 pivotal trial ongoing; CTX130 RMAT designation for CTCL; additional data expected in 2022.

## SEC filing metadata
- accession: 0000950170-22-020834
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/0000950170-22-020834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/crsp-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020834
- JSON: https://secwatch.observer/filing/0000950170-22-020834.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020834.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported third quarter ended September 30, 2022 results: revenue $0.1 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $0.1 million
  - Result: reported results
  source text: Revenue: Total collaboration revenue was $0.1 million for the third quarter of 2022, compared to $0.3 mill
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/0000950170-22-020834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.